共 50 条
- [31] Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinomaONCOLOGY, 2007, 72 : 67 - 71Yau, ThomasChan, PierreWong, HildaNg, Kelvin K.Chok, Siu-HoCheung, Tan-ToLam, VincentEpstein, Richard J.Fan, Sheung-TatPoon, Ronnie T. P.
- [32] Molecular pathogenesis and systemic therapies for hepatocellular carcinomaNature Cancer, 2022, 3 : 386 - 401Josep M. LlovetRoser PinyolRobin K. KelleyAnthony El-KhoueiryHelen L. ReevesXin Wei WangGregory J. GoresAugusto Villanueva
- [33] Molecular pathogenesis and systemic therapies for hepatocellular carcinomaNATURE CANCER, 2022, 3 (04) : 386 - 401Llovet, Josep M.Pinyol, RoserKelley, Robin K.El-Khoueiry, AnthonyReeves, Helen L.Wang, Xin WeiGores, Gregory J.Villanueva, Augusto
- [34] Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic TherapiesCLINICAL CANCER RESEARCH, 2022, 28 (16) : 3443 - 3451Kudo, MasatoshiMontal, RobertFinn, Richard S.Castet, FlorianUeshima, KazuomiNishida, NaoshiHaber, Philipp K.Hu, YouyouChiba, YasutakaSchwartz, MyronMeyer, TimLencioni, RiccardoLlovet, Josep M.
- [35] The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysisTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17Peng, WeiPan, YangxunXie, LanYang, ZhoutianYe, ZhiweiChen, JinbinWang, JunchengHu, DandanXu, LiZhou, ZhongguoChen, MinshanFang, AipingZhang, Yaojun
- [36] First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future TrialsLIVER CANCER, 2021, : 75 - 84Cabibbo, GiuseppeReig, MariaCelsa, CiroTorres, FerranBattaglia, SalvatoreEnea, MarcoRizzo, Giacomo Emanuele MariaPetta, SalvatoreCalvaruso, VincenzaDi Marco, VitoCraxi, AntonioSingal, Amit G.Bruix, JordiCamma, Calogero
- [37] FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALSDIGESTIVE AND LIVER DISEASE, 2021, 53 : S107 - S107Cabibbo, G.Celsa, C.Battaglia, S.Enea, M. .Rizzo, G. E. M.Busacca, A.Petta, S.Calvaruso, V.Di Marco, V.Craxi, A.Camma, C.
- [38] Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Marinelli, SaraGranito, AlessandroTerzi, EleonoraLeoni, SimonaPiscaglia, FabioVenerandi, LauraBolondi, Luigi
- [39] Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experienceONCOLOGIST, 2024,Marell, PaulinaKournoutas, IoannisGile, JenniferPeersen, AninaShah, PriyanshiBabiker, HaniKankeu, Lionel FonkouaWashburn, LeslieGraham, RondellTruty, MarkStarlinger, PatrickHalfdanarson, ThorvardurJin, ZhaohuiJatoi, AminahMcwilliams, RobertBorad, MiteshBekaii-Saab, Tanios S.Mahipal, AmitOu, Fang-ShuTran, Nguyen H.